Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDG-PET evaluation of cerebral metabolism changes induced by R-CHOP chemotherapy in lymphoma patients
2009-016848-39Phase 4Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab in non-Hodgkin lymphoma (NHL), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoints: Cerebral FDG uptake (SUV) changes over time and Association between SUV and neuropsychological test performance. Started Nov 2009; status: active.
02
Drugs
cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2009-016848-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016848-39.